Download PDF

1. Company Snapshot

1.a. Company Description

NeueHealth, Inc., a healthcare company, provides various healthcare services for health consumers, providers, and payors in the United States.It operates through two segments: NeueCare and NeueSolutions.The NeueCare segment delivers healthcare services to ACA marketplace, medicare, and medicaid through owned and affiliated clinics.


It operates risk-bearing clinics under the Centrum Health, AssociatesMD, and Premier Medical Associates brand names.The company also offers integrated system care solution, such as embedded pharmacy, laboratory, radiology, and population health focused specialty services; and chronic care management, transitions of care, and referral management services.The NeueSolutions segment enables providers and medical groups to succeed in performance-based arrangements; and participates in the centers for healthcare access to medicare beneficiaries.


The company was formerly known as Bright Health Group, Inc.and changed its name to NeueHealth, Inc.in January 2024.


NeueHealth, Inc.was incorporated in 2015 and is headquartered in Doral, Florida.

Show Full description

1.b. Last Insights on NEUE

NeueHealth, Inc.'s recent stock performance has been driven by the pending merger with New Enterprise Associates (NEA). The merger has sparked a series of investigations by law firms, including Bronstein, Gewirtz & Grossman, LLC, which is encouraging investors to learn more about the investigation. This increased scrutiny has likely boosted investor confidence, as the merger is expected to bring significant value to shareholders.

1.c. Company Highlights

2. NeueHealth's Strong Q2 Performance

NeueHealth reported $209.1 million in revenue and $19 million in adjusted EBITDA for the second quarter of 2025, contributing to $32.5 million in the first half of the year. The company's EPS came in at -$1.68, beating analysts' estimates of -$4.77. This strong financial performance was driven by a 45% increase in consumers served, reaching 694,000. The company's revenue growth was accompanied by a significant increase in consumers served across various segments, including the ACA Marketplace, senior care business, and Medicaid.

Publication Date: Aug -20

📋 Highlights
  • Strong Q2 2025 Revenue and EBITDA: Reported $209.1M revenue and $19M adjusted EBITDA, with $32.5M total for H1 2025.
  • Consumer Growth Surge: Served 694,000 consumers (45% YoY growth), including 485,000 in ACA Marketplace and 65,000 in senior care.
  • Medicaid Expansion: Served 144,000 consumers via provider enablement partnerships, driving performance-based arrangements.
  • NeuePulse Platform Development: Evolving data/analytics into an end-to-end value-based care platform, supported by $234.4M in cash and investments.
  • Segment Performance: NeueCare ($91.6M revenue, $23.2M operating income) outperformed NeueSolutions ($120M revenue, $2.6M operating income).

Segment Performance

NeueHealth's segments, NeueCare and NeueSolutions, reported revenue of $91.6 million and $120 million, respectively. Operating income for NeueCare was $23.2 million, and NeueSolutions was $2.6 million. The company's senior care business grew, serving 65,000 consumers across Medicare Advantage, ACO REACH, and MSSP. Medicaid served 144,000 consumers, primarily through the provider enablement business, which focuses on partnerships with provider groups to drive performance-based arrangements.

Valuation and Growth Prospects

With a P/S ratio of 0.07 and an EV/EBITDA ratio of 1.38, the company's valuation appears relatively low. Analysts estimate next year's revenue growth at 7.0%, which could potentially drive a re-rating of the stock. According to a staff report, "the company's data and analytics capabilities are being evolved into an end-to-end value-based care enablement platform called NeuePulse," which could be a key growth driver. The company's ROIC and ROE are 18.89% and 14.26%, respectively, indicating a strong ability to generate returns on investment.

Balance Sheet and Liquidity

NeueHealth has a strong balance sheet with $234.4 million in total cash and investments. The company anticipates a transaction to go private led by an affiliate of one of its largest investors, NEA, to close in mid-to-late 2025. The net debt to EBITDA ratio is 2.52, which is relatively manageable. However, the free cash flow yield is -125.28%, indicating that the company is currently generating negative free cash flow.

3. NewsRoom

Card image cap

NeueHealth Announces Closing of Take-Private Transaction

Oct -02

Card image cap

NeueHealth, Inc. (NEUE) Q2 2025 Earnings Call Transcript

Aug -08

Card image cap

Transcript : NeueHealth, Inc., Q2 2025 Earnings Call, Aug 07, 2025

Aug -07

Card image cap

NeueHealth Reports Second Quarter 2025 Results

Aug -07

Card image cap

NeueHealth to Host Second Quarter 2025 Earnings Conference Call on August 7, 2025

Jul -17

Card image cap

NeueHealth, Inc (NEUE) Q1 2025 Earnings Call Transcript

May -11

Card image cap

NeueHealth Reports First Quarter 2025 Results

May -08

Card image cap

NeueHealth to Host First Quarter 2025 Earnings Conference Call on May 8, 2025

Apr -23

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (1.00%)

6. Segments

NeueSolutions

Expected Growth: 1.0%

NeueSolutions' 1.0 growth driven by increasing adoption of value-based care, rising demand for healthcare analytics, and strategic partnerships. NeueHealth's focus on population health management, care coordination, and patient engagement also contributes to growth. Additionally, the platform's ability to integrate with existing healthcare systems and provide actionable insights fuels expansion.

NeueCare

Expected Growth: 1.0%

NeueCare's 1.0 growth driven by increasing adoption of value-based care, rising demand for Medicare Advantage, and NeueHealth's strategic partnerships with healthcare providers, enabling better patient outcomes and cost savings.

Corporate & Eliminations

Expected Growth: 1.0%

NeueHealth, Inc.'s Corporate & Eliminations segment growth of 1.0 is driven by strategic cost management, efficient allocation of resources, and effective capital structure management. Additionally, the company's focus on value-based care and population health management initiatives contributes to this growth.

7. Detailed Products

NeueHealth Platform

A comprehensive healthcare platform that integrates care delivery, payment, and analytics to provide a seamless experience for patients, providers, and payers.

Value-Based Care Solutions

A suite of solutions that enable healthcare providers to transition from fee-for-service to value-based care models, improving patient outcomes and reducing costs.

Care Coordination Services

A range of services that facilitate care coordination, including care management, care transitions, and patient engagement.

Population Health Analytics

A data analytics platform that provides insights into patient populations, enabling healthcare providers to identify trends, track outcomes, and optimize care delivery.

Revenue Cycle Management

A comprehensive revenue cycle management solution that optimizes claims processing, billing, and payment posting.

8. NeueHealth, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

NeueHealth, Inc. operates in a niche market with limited substitutes, reducing the threat of substitutes.

Bargaining Power Of Customers

Customers have some bargaining power due to the availability of alternative healthcare providers, but NeueHealth's unique value proposition and strong customer relationships mitigate this power.

Bargaining Power Of Suppliers

NeueHealth, Inc. has a diversified supplier base, reducing the bargaining power of individual suppliers.

Threat Of New Entrants

The healthcare industry is highly regulated, and new entrants face significant barriers to entry, but NeueHealth, Inc. still faces a high threat from new entrants due to the growing demand for healthcare services.

Intensity Of Rivalry

The healthcare industry is highly competitive, but NeueHealth, Inc.'s focus on value-based care and its strong market position reduce the intensity of rivalry.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 1380.81%
Debt Cost 7.88%
Equity Weight -1280.81%
Equity Cost 7.88%
WACC 7.88%
Leverage -107.81%

11. Quality Control: NeueHealth, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
NeueHealth

A-Score: 4.8/10

Value: 9.8

Growth: 3.6

Quality: 4.6

Yield: 0.0

Momentum: 7.5

Volatility: 3.7

1-Year Total Return ->

Stock-Card
Artivion

A-Score: 4.5/10

Value: 4.8

Growth: 4.4

Quality: 4.9

Yield: 0.0

Momentum: 8.5

Volatility: 4.7

1-Year Total Return ->

Stock-Card
Delcath Systems

A-Score: 3.9/10

Value: 1.2

Growth: 5.8

Quality: 6.5

Yield: 0.0

Momentum: 8.0

Volatility: 2.0

1-Year Total Return ->

Stock-Card
Unicycive Therapeutics

A-Score: 3.6/10

Value: 6.4

Growth: 4.6

Quality: 3.6

Yield: 0.0

Momentum: 6.5

Volatility: 0.7

1-Year Total Return ->

Stock-Card
Accuray

A-Score: 3.6/10

Value: 7.8

Growth: 5.0

Quality: 2.2

Yield: 0.0

Momentum: 4.0

Volatility: 2.7

1-Year Total Return ->

Stock-Card
Inovio Pharmaceuticals

A-Score: 1.9/10

Value: 6.4

Growth: 0.3

Quality: 3.2

Yield: 0.0

Momentum: 0.5

Volatility: 1.0

1-Year Total Return ->

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

6.75$

Current Price

6.75$

Potential

-0.00%

Expected Cash-Flows